Balb/c 8. ! H $!!. $Z " # a !. >O!% :! 4 *+/0! !./ (Malkinson A.M. ;<c<) // T4 T/ U " 3 D 1. '(!)*# - #&

Transcription

1 * )'( : %,!", 7 60 D +, Balbc "#% Ph.D!, : 47. 9,0: fkoohdani@sina.tums.ac.ir '(!)*# - #& #&, "#%,!! "#% (+ : 4; => 0..! 0 (#- : 455?-70: 0.,! *,!!, *#1 ( 0+!+ - 0.!, 6+ - : +,0 0.!'D : 80,C! ''' : :, : E; "% &' ( " #! D : F7-6.'#!) ;; (:! ) (nbred) 8 9 (Balbc )45 3 1! '+.+0! : G 8 ( "! 9 ". *'. 3 :?!..''# 94 :?.. %.= H *'. BC " ". :EF G! :?.'# 8! *D. (A mgkgday).'!k! '#% L% : K 1 mgkgday..''#.o.n8 ' Q# " R.= P :'K@ 3.NO.' G).N8 '.? M G :?! : H,.O?!.'# '>94 >O!%!%"ES :?.! (T4 U " V8 D :EF.O?!.O! (p ) #!!>+ C &>O :?. 54 '!K!.# '!>+ *= &>O :? " '!K! C.'! X Y X " W :J0. Z :!+7.#^?.! H! (Nakagawa K. et al. P)! H!!. Z " # a Schottenfeld D. ). C ;P ".(;A!. >O!% :! 4 *+0!!# :!= 3. " "% &' (!. (Malkinson A.M. ;c) T4 T U " 3 : O :'F. CZ " :'[ ^_ 9T.'>4 > :! 0] ' #. #! Z %1! Z.(Eichholzor M. P) Landis S.H. )! %! K " a F ND, &!.(et al. ; b0! Z " #

2 K7 7G 9,0: A! (R> " 3 ) ''# 94 :?. GK!?.K *.''# C) R=@ :!= : h!.! ' ^ _ ".N8 ' &Z '' n] B0!) " '+.=!.'!K G? ;P;.= ;; #.O 0 #! >+ '>#! " ( #) G? ;P (:! #) *' GK! (C) &>O :?.9!K "_%.N8 ' '!K :!= K+ '#% L% ".N8 '..! '.\[ ]! &N] A mgkg (U) T>O :?.ND!. (% 9' 'NO) TC G L% " : h!. :?.'# BC "! " :EF G :?.'!O :!= K+ BC ] G! :?. m@!.> L%..= H *'. BC " " '>?., (A1 mg;ml) % '#%! " " R.O Oq. G"r '#.!! BN0 XN Ps...O.' XN ;9). L% RS 3,; ml. " l L% \.'!K! 1 mgkgday Q# " R.= P :'K@ %;! V8 %..O.N8 '. & O *FEZ 5W " R '# :!!! ''# :!% #CS! :'! T ' :\"% ' N ;!+. +0@ % "?.? ' ku! T4.!. N.''# ( ^?:K# GK CK :'# Lh "?L%.N.'# G)! ' *D..K ;P!' " *'! C! ".Z_?v@ KF :? %.? *D F >O :d. >O!%. 5#!. 4! e% # O!.+0 &' 3 4 T ".O!. f *]!.NK " 'K \ Z.(Markinson A.M. P;)'.? " gnh i " Z! " B]! :!=.! Z!) (*O ) :! ( >F. ;A & " 5@.'# Malkinson A.M. ) '# kl 4! # Kh " D ^ _!! ( P;!!" '. N * mdl8! :!. (Azevedo Z. et al. PP)!! NNK R T% n :! CZ?'! K CZ :! ( >F. Z *].(Chan P.C. ;A) :'#.8># C 4 ; alpha,.o '! N5@ *+0! '+ :" ' % a% P(OH)P-D1 4 O *. ( &' Eisman J.A. et al. ;c, )'! O E Lokeshwar B.L. et al. ;, Cross H.S. et al. P1, Mantell D.J. et al. P, K.. ( Nakagawa K. et al. P i\ '' i : X. Z.!8 i!" K " on ik &>Y * W X>5 XN5@ *+0 p.. ^ U>. B]. o i &'!) "?N! * W X in *D. ( kl " R).'# X Z Balbc 3! vivo :. 8 R.= hk Balbc 3!'F 1.!l *D. 4 " '8 "

3 ... +, --G J O8. '= w = ' *+, 9H. 8 b0 ".4 *D.! bn4_ :'! e% "ES :? " ( M!% :'# :!! xh *+,.NO.'!.'! N Q ".+0 >O!% \ N '# ( ; }PR F)e%!% '! 8 ( &N '# :'! r'e?.o! CK &N '!! K838 *Dl8 # &N r 5 " >H R F)>O!% ~ "! :'# :'(1 ; 1 0! '!!?.# u r" n.o '# :'! :! #. Z O. &N q=! + '>5K >O.'! :'#.Z.4( Q " yl8 Q " G> O k Z.4( % K '# Gr! >[K.! TO b, me O '! " "! m5_.o " C n5 meo Gr! :'# :' " C.! ( &N :" '.! :'# :!! xh Z.! %.'! #!? %.4 :!5. 5+ # &N.4( &N.'!% r 5 " N \ (!.+0! :'# :' r 55.r N '# e%!. " '#.O '! r'e? \! N# '>H.4 >[K.! % (Hyperchromatism) w (Pleomorphism).''# :' Gr! G!%! M &>O :?!.+0! 9 :?!.O!.' :' G>O # ''# :!% 3.K G) L ^.'#. h, (T4 R 3 9N RS CK 5@ ".O Gr G? GK. & " *5W " '+ '# >! 5% v4h.._% &N]!!" " R Gr GK ]0 y "e R N4OK 3 NC?.(;1A!) ''# C%w ' 'E GK.+0 xh. ' ' KaC. G"r...! ; KaC +0@ 4=.'# Y! *D..+0.Y Yq! ' ".+0 G\>..'#. RF lh K >O! ( >O!.K GK!! y8 (T :'' :?.! e% G>O G!% "ES *+, Q#. f *FEZ.''# '>.5Z " :!= \'. 54 :? " (!.'# + % "% : H, K v@! B]. p :'#!) (T * z :' u. :'#.e.!!! &>O :? " 3 (.+0 Z! 3 (.N8 ' ] :? " R G "! :! 3! G! "! :! 3 \! #. " R BC T>O :?!.'! F '>H " R :'!.(; &')!= {=?.+0 Z! (U) :' =.+,.? M &>O :?!'+! '+.+0! \! :?!!.'

4 K7 7G 9,0:!)! D W.' 3!.N8 ' ] :?!.O %!. G"r G G! "! :! 3.! (T.+,.? M.O '! BC.O ' :!K 0 N5@ *+0 ' :' %.)!!" ' 8ƒ. &E]K,!@ Schlatter J. )' C 8! % " ' (and Lute W.K. ;, Chan P.C. ;A ( >F. % W m D l 8 % K * W v Oq me Z K.!# rz # :! " R # F '>H v@+ a '#!! mr K.O! {= BC # W (Ps ml;ml ) &N]!. O^ 3 :!K :'>! U.. ' :! '! X# :! ir C *' >H! '> K * W 'K *+0! >[K.'# 3 a F O F '. O :' # 0.O ( Nakagawa K. et al. P)!!? K4NOS.'# 0 O^ 3 a! K : 0 F >F.. Z :\..!! *].. Z " # a!8 :d K " K 08 O K,.+0 " D p. 0!) " \! *+0. 'ƒ!#!> 'K >[K.!# G) Z.>"!! " :!= '+ z ( >F. D &N] * W!!?!> >[K.!? : K :?! '# :'! G>O 9 G!%.(; &')! :'# G!% n D! (G>O G!%) :'#!) QK) (p ) #!!>+ *= &>O :? : K :?!!).O!.? M.(P &')!5!>+ &>O ".+0 ] gnh :?!>+.0.(1 &') ' 98' *+, Q# U : M %A! (U) T> O :?!. +0! :! # %c (G>O!% mk) 3! ".'#!) (G!% m O ) Chan P.C. ;A, ) :'# 'ƒ C *+0 Q#!! *=. (minitov E.N. ; *+0! :'#!) Q R>!!O :]! *=!. ' gnh '# kl *+!! '+ " ' 'ƒ.! " *+0 \K.'>K BC Q#.O ",.+0! :!! 3..= H *'. :?!!)!>+ *= \! '# W '..O # '! &>O :? " * W O! K.+0 '>H. > :'# G) i!.!" 0! % a% * W.>"! 9 %.9!K!8 " "?N. W 94 *+0! (ECM) XN V8 R. XN X?'>54H Y ECM&E]K, " i?n v ' :'# :!! 54 i4y i &N X@F + Yadoh K. et al. ;, Nakagawa K. et al. ).+0.(P, Nakagawa K. et al. P

5 ... +, --G J K,.?'>4.( s;1; (T :? " >[K,C5 #C GNF :\! :'! #C GNF :\! #C > * " :!= :\! #CS! ' *K" " C v>.'>k C\S *+0! 98'.!# :!=.K 9) " '+ :N0 C5 #C GNF :\!.N. B] :K# ] Z) :'# K G>O G!% +5Z *! '+ :? :'# "% s (%;) s (C) &>O 1 (%A) P (%s) (U) P (%s) 1 (%A) (U+D) D1 (%;) (C) &>O :! ;(%P) 1 (%A) ; (%P) (U) P (%;) P (U+D) D1 (%;) (C) &>O :! s (%s) 1 (%1) 1 (%1) ; (U) P (%PcA) (%;s) (U+D) D1 K +5Z.+, 'D!! '+ 'D!! '+ :? ; &>O ; * 1 1 PcA P ;s p* K 98' , 'D!! '+ 'D!! '+ :? ; &>O ; s s A A

6 K "# ; "# %& ' ( %& )**!! 7 D1 7 G 9,0:

7 ... +, --G J (M)+, -"* (M),+, -", "#.0(% &)**! : O- mutations in lung adenomas induced in neonatal BALBC mice with - bromodesoxyuridine inection followed by urethane treatment. Vopr onkol. 35():sP}. Landis S.H., Murray T., Bolden S. and Wingo P.A. (;) Cancer statistics. CA Cancer J Clin. 38:c}1;. Landis S.H., Murray T., Bolden S. and Wingo P.A. (;) Cancer statistics. CA Cancer J Clin. 38:c}1;. Lokeshwar B.L., Schwartz G.G., Selzer M.G., Burnstein K.L., Zhuang S.H., Block N.L. and Binderup L. (;) nhibition of prostate cancer metastasis in vivo: a comparison of ;, Pdihydroxyvitamin D (calcitriol) and EB;c. Cancer Epidemiol., Biomark. Prev. 9: Ps;}Psc. Malkinson A.M. (;c) The genetic basis of susceptibility to lung tumors in mice. Toxicology. 53:Ps;}P;. Malkinson A.M. (P;) Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer. :PA}P. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B. and Canfield A.E. (P) ;P-Dihydroxyvitamin D1 inhibits i 3 X># (;1A) 9N4,i!. :\! * ic% w Azevedo Z., Couto J.A. and Hogg T. (PP) Citrulline as the main precursor of ethyl carbamate in model fortified wines inoculated with lactobacillus hilgardii: a marker of the levels in a spoiled fortified wine. Letters in Applied Microbiology. 3:1P}1A. Chan P.C. (;A) NTP technical report on toxicity studies of urethane in drinking water and urethane in ˆ ethanol administered to F1ssN rats and BAC1F; mice. Toxic Rep Ser. 5:;};,A;}, B;} passim. Cross H.S., Kallay E., Farhan H., Weiland T. and Manhardt T. (P1) Regulation ofextrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention.recent Results Cancer Res. 63: s;1}sp. Eichholzer M. (P) Nutrition and cancer. Ther Umsch. 57(1):;sA};. Eisman J.A., Barkla D.H. and Tutton P.J.M. (;c) Suppression of in vivo growth of human cancer solid tumor xenografts by ;P-dihydroxyvitamin D1. Cancer Res. 37:P;}P. mianitov E.N., Togo A.V. and Anisimov VN (;) Search for Ki-ras codon A;

8 K7 7G 9,0: dietary exposure levels. Food Chem Toxicol. 9(1):P};;. Schottenfeld D. (;A) Epidemiology of the lung. n: Pass H.., Mitchell J.B., Johnson D.H., Turrisi A.T., (Eds): Lung Cancer Principle, and Practice. Philadelphia, PA: Lippincott-Raven Press. 1}P1. Yadoh K., Matsuno H. and Kimura T. (;) ; alpha, P-dihydroxyvitamin D1 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B;A mouse melanoma. J Lab Clin Med. (P):;P}c. angiogenesis in vitro and in vivo. Circ. Res. 97:P;s}PP. Nakagawa K., Kawaura A., Kato S., Takeda E. and Okano T. (P);P- Dihydroxyvitamin D1 is a preventive factor in the metastasis of lung cancer. Carcinogenesis. 6(P):sP}ss. Nakagawa K., Sasaki Y., Kato S.H., Kubodera N. and Okano T. (P) PP- Oxa};>,P-dihydroxyvitamin D1 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. in press. Schlatter J. and Lutz W.K. (;) The carcinogenic potential of ethyl carbamate (urethane):risk assessment at human